Australia: High Court unanimously invalidates Crestor patent, but starting point is still a numbers game

What it means:

  • The final patent protecting Crestor, AstraZeneca's blockbuster anti-cholesterol drug, has been invalidated by the High Court.
  • The High Court's decision to avoid clarifying the "starting point" means that, at least under the Patents Act 1990, the starting point for assessing an inventive step must be the common general knowledge rather than the disclosure of the patent, for example through the adoption of a "problem-solution" approach as Apotex v Sanofi had indicated.
  • The High Court decision opens the door to damages claims by generic manufacturers who were restrained from launching rosuvastatin products during the proceedings. The manufacturers may however face difficulties in accurately quantifying their damages.
  • AstraZeneca may also face a claim for damages by the Commonwealth, akin to other claims the Commonwealth is currently pursuing.

The High Court recently handed down its decision in the ongoing battle between AstraZeneca and three generic companies (Apotex, Watson and Ascent) over AstraZeneca's Crestor® (rosuvastatin). The High Court has affirmed previous rulings that the only patent the subject of the appeal is invalid.

The primary issue on appeal was whether or not the claimed invention possessed an inventive step. The High Court, having found no inventive step was disclosed, declined the opportunity to consider other significant issues raised in the appeal.

The Court was required to consider the construction and interpretation of sections 7(2) and 7(3) of the Patents Act 1990, which relate to the use of prior art publications. When conducting searches to identify documents relevant to inventive step, experts for the generic companies identified multiple documents which disclosed novel compounds for the treatment of hypercholesterolemia. One document disclosed rosuvastatin, the active ingredient in Crestor, while another article disclosed an alternative compound. A third document disclosed that rosuvastatin was then in clinical trials. The experts had utilised a combination of these documents as multiple sources of information, none of which formed part of the common general knowledge, with a view to identifying single documents that were 'regarded as relevant' as is required by section 7(3) of the Patents Act. AstraZeneca argued that utilising multiple documents to identify the most relevant course to pursue was in breach of section 7(2).

The High Court agreed with the decision of the Full Federal Court, finding that section 7(2) precluded the use of a combination of documents in determining whether the patent disclosed an inventive step, but not for the purposes of satisfying the 'regarded as relevant' requirement in section 7(3). The comparison of documents for the purposes of deciding that a document was relevant was within the scope of section 7(2).

Having dismissed the appeal on this basis, the High Court declined to take a position on the validity of the "starting point" analysis for an assessment of whether an inventive step is disclosed. This area of patent law has been in flux since the Full Federal Court decision, which was inconsistent with the earlier Full Federal Court decision in Apotex v Sanofi-Aventis. In the Sanofi-Aventis decision, the Full Federal Court had decided that, with respect to a patent specification which disclosed a 'problem' and its 'solution', the appropriate starting point was the disclosed problem. The Full Federal Court in AstraZeneca had decided that the reasoning in Sanofi-Aventis was, at most, relevant for the purposes of the Patents Act 1952. Most commentators awaiting the decision had expected the High Court to rule on whether the "starting point" approach could be followed. Given the Court has elected not to do so, it leaves considerable doubt as to the appropriate starting point for patents granted under the 1952 Act. These patents are, however, diminishing in number, meaning this point may not be litigated again.

AstraZeneca will now face claims for damages from each of the three generic companies pursuant to the undertaking AstraZeneca proffered when it was granted interlocutory injunctions preventing the generics from launching. Quantifying this sum is likely to be complicated by the fact that multiple generic parties will have claims to damages, and determining the respective damage of each will require evidence on the market share each would have had if not restrained.

The Commonwealth may also make a claim for damages under the same undertaking consistent with the Commonwealth's recent position in other cases. Unusually, the Commonwealth's position might well be complicated by the listing, on the same date the Apotex generic was scheduled to list, on the Pharmaceuticals Benefit Scheme of two generic versions of atorvastatin. This listing triggered a mandatory price reduction in the cost of Crestor on that date. Therefore, the Commonwealth's loss is likely be confined to the quantum of damage caused by the delayed application of the price disclosure regime. The result is likely to be that the Commonwealth's damages are significantly reduced, and also far more difficult to quantify. It is also worth noting that the Commonwealth's entitlement to damages under the undertakings are still awaiting judicial opinion.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Rohan Sridhar
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.